{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995333,"version":"4.1.0"},"reference-count":134,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12-HS026393"],"award-info":[{"award-number":["K12-HS026393"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23-AI127935"],"award-info":[{"award-number":["K23-AI127935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Infections due to carbapenem-resistant Enterobacteriaceae (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes. Optimal treatment strategies for CRE infections continue to evolve. A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children. In this review, we provide a framework for antibiotic treatment of CRE infections in children, highlighting relevant microbiologic considerations and summarizing available data related to the evaluation of FDA-approved antibiotics (as of September 2019) with CRE activity, including carbapenems, ceftazidime-avibactam, meropenem-vaborbactam, imipenem\/cilastatin-relebactam, polymyxins, tigecycline, eravacycline, and plazomicin.<\/jats:p>","DOI":"10.1093\/jpids\/piz085","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T07:12:22Z","timestamp":1574838742000},"page":"56-66","source":"Crossref","is-referenced-by-count":81,"title":["Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children"],"prefix":"10.1093","volume":"9","author":[{"given":"Kathleen","family":"Chiotos","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Division of Critical Care Medicine, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Center for Pediatric Clinical Effectiveness, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Antimicrobial Stewardship Program, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Hayes","sequence":"first","affiliation":[{"name":"Antimicrobial Stewardship Program, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Gerber","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Center for Pediatric Clinical Effectiveness, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"},{"name":"Antimicrobial Stewardship Program, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita D","family":"Tamma","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"key":"2020022803101079600_CIT0001","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3201\/eid2111.150548","article-title":"Carbapenem-resistant Enterobacteriaceae in children, United States, 1999\u20132012","volume":"21","author":"Logan","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2020022803101079600_CIT0002","doi-asserted-by":"crossref","first-page":"ofy222","DOI":"10.1093\/ofid\/ofy222","article-title":"Increased 30-day mortality associated with carbapenem-resistant Enterobacteriaceae infections in children","volume":"5","author":"Chiotos","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020022803101079600_CIT0003","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/INF.0000000000001188","article-title":"Carbapenem-resistant Enterobacteriaceae infections in children: an Italian retrospective multicenter study","volume":"35","author":"Montagnani","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0004","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/INF.0000000000001499","article-title":"Clinical and bacterial risk factors for mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infections in India","volume":"36","author":"Nabarro","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0005"},{"key":"2020022803101079600_CIT0006","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"2020022803101079600_CIT0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"2020022803101079600_CIT0008","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1128\/JCM.02338-16","article-title":"Comparison of 11 phenotypic assays for accurate detection of carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Tamma","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2020022803101079600_CIT0009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/21505594.2016.1185577","article-title":"Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae","volume":"8","author":"Banerjee","year":"2017","journal-title":"Virulence"},{"key":"2020022803101079600_CIT0010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"2020022803101079600_CIT0011","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.02636-14","article-title":"Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network","volume":"58","author":"van Duin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0012","doi-asserted-by":"crossref","first-page":"396","DOI":"10.15585\/mmwr.mm6713e1","article-title":"Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms\u2013United States, 2006\u20132017","volume":"67","author":"Woodworth","year":"2018","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"2020022803101079600_CIT0013","doi-asserted-by":"crossref","first-page":"e01440","DOI":"10.1128\/AAC.01440-17","article-title":"Risk factors for colonization or infection with carbapenem-resistant Enterobacteriaceae in children: a multicenter study","volume":"61","author":"Chiotos","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/INF.0000000000000471","article-title":"Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States","volume":"34","author":"Pannaraj","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciy576","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam, or both? Clinical and formulary considerations","volume":"68","author":"Pogue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2020022803101079600_CIT0017","doi-asserted-by":"crossref","first-page":"727","DOI":"10.15585\/mmwr.mm6725a6","article-title":"Notes from the field: domestically acquired Verona integron-mediated metallo-beta-lactamase-producing Enterobacteriaceae\u2013Indiana, 2016\u20132017","volume":"67","author":"Shannon","year":"2018","journal-title":"MMWR Morbid Mort Wkly Rep"},{"key":"2020022803101079600_CIT0018","doi-asserted-by":"crossref","first-page":"ofw090","DOI":"10.1093\/ofid\/ofw090","article-title":"Metallo-beta-lactamase (MBL)-producing Enterobacteriaceae in United States children","volume":"3","author":"Logan","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2020022803101079600_CIT0019","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/jpids\/piw025","article-title":"First report of a Verona integron-encoded metallo-\u03b2-lactamase-producing Klebsiella pneumoniae infection in a child in the United States","volume":"5","author":"Tamma","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020022803101079600_CIT0020","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.45.30062","article-title":"Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015","volume":"20","author":"Albiger","year":"2015","journal-title":"Euro Surveill"},{"key":"2020022803101079600_CIT0021","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2020022803101079600_CIT0022","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1128\/AAC.00099-14","article-title":"Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents","volume":"58","author":"Almaghrabi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0023","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1128\/AAC.00158-08","article-title":"Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States","volume":"52","author":"Endimiani","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0024","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.PLAS-0006-2013","article-title":"Plasmid-mediated quinolone resistance","volume":"2","author":"Jacoby","year":"2014","journal-title":"Microbiol Spectrum"},{"key":"2020022803101079600_CIT0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2011.09.014","article-title":"Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae","volume":"39","author":"Little","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2020022803101079600_CIT0026","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0027","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature13205","article-title":"Structure of the AcrAB-TolC multidrug efflux pump","volume":"509","author":"Du","year":"2014","journal-title":"Nature"},{"key":"2020022803101079600_CIT0028","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijantimicag.2018.03.020","article-title":"Role of association of OmpK35 and OmpK36 alteration and blaESBL and\/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae","volume":"52","author":"Hamzaoui","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020022803101079600_CIT0029","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2020022803101079600_CIT0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/JCM.01263-11","article-title":"Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital","volume":"50","author":"Yang","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020022803101079600_CIT0031","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3389\/fmicb.2016.02054","article-title":"Altered outer membrane transcriptome balance with AmpC overexpression in carbapenem-resistant Enterobacter cloacae","volume":"7","author":"Majewski","year":"2016","journal-title":"Front Microbiol"},{"key":"2020022803101079600_CIT0032","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"2020022803101079600_CIT0033","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/AAC.01585-15","article-title":"Role of the outer membrane and porins in susceptibility of \u03b2-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam","volume":"60","author":"Pag\u00e8s","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0034","doi-asserted-by":"crossref","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0035","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0036","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020022803101079600_CIT0037","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020022803101079600_CIT0038","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2020022803101079600_CIT0039","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/pbc.22051","article-title":"Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population","volume":"53","author":"Courter","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2020022803101079600_CIT0040","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2020022803101079600_CIT0041","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","author":"Daikos","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020022803101079600_CIT0042","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020022803101079600_CIT0043","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0044","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0046","author":"Food and Drug Administration"},{"key":"2020022803101079600_CIT0047","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to &lt;18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0048","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to &lt;18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0049","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.01682-10","article-title":"In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes","volume":"55","author":"Citron","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0050","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0051","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0052","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0053","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1128\/AAC.02841-15","article-title":"Assessment of the in vitro activity of ceftazidime-avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM Global Surveillance Study, 2012 to 2014","volume":"60","author":"Hackel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0054","doi-asserted-by":"crossref","first-page":"e00449","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0055","doi-asserted-by":"crossref","first-page":"e01964","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0056","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0057","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0000000000002344","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children &lt;5 years of age","volume":"38","author":"Iosifidis","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0058","doi-asserted-by":"crossref","first-page":"e02101","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0059","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2020022803101079600_CIT0060","doi-asserted-by":"crossref","first-page":"e01904","DOI":"10.1128\/AAC.01904-17","article-title":"In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0061","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2020022803101079600_CIT0062","doi-asserted-by":"crossref","first-page":"e01694","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0063","doi-asserted-by":"crossref","unstructured":"Lomovskaya O , CastanheiraM, VazquezJ, et al Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGO II (a phase 3 study of the treatment of CRE infections) [Abstract 1874]. In: IDWeek 2017. San Diego, CA; 4\u20138 October 2017.","DOI":"10.1093\/ofid\/ofx163.1404"},{"key":"2020022803101079600_CIT0064","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/phar.2187","article-title":"Pharmacokinetics of the meropenem component of meropenem-vaborbactam in the treatment of KPC-producing Klebsiella pneumoniae bloodstream infection in a pediatric patient","volume":"38","author":"Hanretty","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2020022803101079600_CIT0065"},{"key":"2020022803101079600_CIT0066","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0067","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020022803101079600_CIT0068","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0069","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","author":"Motsch","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0070"},{"key":"2020022803101079600_CIT0071"},{"key":"2020022803101079600_CIT0072"},{"key":"2020022803101079600_CIT0073","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0074","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020022803101079600_CIT0075","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0076","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/1469-0691.12697","article-title":"Treating infections caused by carbapenemase-producing Enterobacteriaceae","volume":"20","author":"Tzouvelekis","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020022803101079600_CIT0077","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0078","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0079","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020022803101079600_CIT0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020022803101079600_CIT0081","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.03007-15","article-title":"Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"60","author":"Gomez-Simmonds","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0082","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s12879-016-1979-z","article-title":"A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome","volume":"16","author":"de Maio Carrilho","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2020022803101079600_CIT0083","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2014.07.010","article-title":"Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins","volume":"21","author":"de Oliveira","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2020022803101079600_CIT0084","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","article-title":"Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2020022803101079600_CIT0086","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijantimicag.2018.06.012","article-title":"Colistin resistance in carbapenemase-producing Klebsiella pneumoniae bloodstream isolates: evolution over 15 years and temporal association with colistin use by time series analysis","volume":"52","author":"Tansarli","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020022803101079600_CIT0087","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1128\/AAC.00246-16","article-title":"First detection of the mcr-1 colistin resistance gene in Escherichia coli in Italy","volume":"60","author":"Cannatelli","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0088","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2020022803101079600_CIT0089","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/cid\/cit453","article-title":"Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center","volume":"57","author":"Akajagbor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0090","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/AAC.02634-15","article-title":"Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B","volume":"60","author":"Rigatto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0091","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0092","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1128\/AAC.06426-11","article-title":"Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill","volume":"56","author":"Mohamed","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0093","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/cid\/civ964","article-title":"Updated US and European dose recommendations for intravenous colistin: how do they perform?","volume":"62","author":"Nation","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0094","first-page":"565","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0095","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0096","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0097","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3390\/antibiotics8020038","article-title":"Polymyxins: to combine or not to combine?","volume":"8","author":"Perez","year":"2019","journal-title":"Antibiotics"},{"key":"2020022803101079600_CIT0098","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/INF.0000000000001655","article-title":"Colistin use in neonates and children with infections due to carbapenem-resistant bacteria","volume":"36","author":"Antachopoulos","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0099","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/INF.0000000000001263","article-title":"Pharmacokinetics of colistin following a single dose of intravenous colistimethate sodium in critically ill neonates","volume":"35","author":"Nakwan","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0100","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1128\/AAC.01799-09","article-title":"Serum and cerebrospinal fluid levels of colistin in pediatric patients","volume":"54","author":"Antachopoulos","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0101","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/cid\/cix757","article-title":"Colistin area under the time-concentration in children treated with intravenous loading dose and maintenance therapy","volume":"66","author":"Mesini","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0102","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/cid\/cix1048","article-title":"Dose suggestions for intravenous colistin in pediatric patients: caution required","volume":"66","author":"Nation","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0103","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/INF.0000000000000117","article-title":"The use of colistin in critically ill children in a pediatric intensive care unit","volume":"33","author":"Karbuz","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0104","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1097\/PCC.0b013e31828a740f","article-title":"Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients","volume":"14","author":"Kapoor","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"2020022803101079600_CIT0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/INF.0b013e3182703790","article-title":"The use of intravenous colistin among children in the United States: results from a multicenter, case series","volume":"32","author":"Tamma","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0106","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0107","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpt.981","article-title":"Population pharmacokinetics of polymyxin B","volume":"104","author":"Manchandani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2020022803101079600_CIT0108","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/592577","article-title":"Pharmacokinetics of intravenous polymyxin B in critically ill patients","volume":"47","author":"Zavascki","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0109","doi-asserted-by":"crossref","first-page":"e01475","DOI":"10.1128\/AAC.01475-17","article-title":"Population pharmacokinetics of polymyxin B in acutely ill adult patients","volume":"62","author":"Miglis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2020022803101079600_CIT0111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijantimicag.2016.07.023","article-title":"Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis","volume":"49","author":"Vardakas","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2020022803101079600_CIT0112","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1186\/s12879-014-0626-9","article-title":"Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study","volume":"14","author":"Siddiqui","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2020022803101079600_CIT0113","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/jpids\/pit049","article-title":"Microbiological and genetic characterization of carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients","volume":"3","author":"Dara","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020022803101079600_CIT0114","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/INF.0b013e318207a7c1","article-title":"Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia","volume":"30","author":"Salvatore","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2020022803101079600_CIT0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14656566.2018.1559817","article-title":"The use of polymyxins to treat carbapenem resistant infections in neonates and children","volume":"20","author":"Thomas","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2020022803101079600_CIT0116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","article-title":"Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010\u20132013)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020022803101079600_CIT0117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2020022803101079600_CIT0118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2014.01.006","article-title":"Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections","volume":"44","author":"Falagas","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020022803101079600_CIT0119","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"2020022803101079600_CIT0120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/cid\/cis969","article-title":"Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit","volume":"56","author":"Sbrana","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020022803101079600_CIT0121","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0122","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.clinthera.2011.12.010","article-title":"Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study","volume":"34","author":"Purdy","year":"2012","journal-title":"Clin Ther"},{"key":"2020022803101079600_CIT0123","first-page":"123","article-title":"Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria","volume":"6","author":"Iosifidis","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020022803101079600_CIT0124","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2020022803101079600_CIT0125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"2020022803101079600_CIT0126","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0127"},{"key":"2020022803101079600_CIT0128"},{"key":"2020022803101079600_CIT0129","doi-asserted-by":"crossref","first-page":"e01989","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020022803101079600_CIT0130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2020022803101079600_CIT0131","first-page":"2246","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms","volume":"73","author":"Castanheira","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020022803101079600_CIT0132","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12879-019-3801-1","article-title":"Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance","volume":"19","author":"Galani","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2020022803101079600_CIT0133","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"2020022803101079600_CIT0134","unstructured":"Connolly LE , JubbAM, O\u2019KeeffeB, et al Plazomicin is associated with improved survival and safety compared with colistin in the treatment of serious infections due to carbapenem-resistant Enterobacteriaceae: results of the CARE study. In: 27th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria; April 22\u201325, 2017."}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/9\/1\/56\/32694068\/piz085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/9\/1\/56\/32694068\/piz085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T20:59:58Z","timestamp":1665089998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/9\/1\/56\/5686153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,21]]},"published-print":{"date-parts":[[2020,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piz085","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,12,21]]}}}